BACKGROUND There are no recent estimates for hypertension-associated medical expenditures. This study aims to estimate hypertension-associated incremental medical expenditures among privately insured US adults. METHODS We conducted a retrospective cohort study using IQVIA's Ambulatory Electronic Medical Records-US data set linked with PharMetrics Plus claims data. Among privately insured adults aged 18 to 64 years, hypertension was identified as having ≥1 diagnosis code or ≥2 blood pressure measurements of ≥140/90 mm Hg, or ≥1 antihypertensive medication in 2021. Annual total expenditures (in 2021 $US) were estimated using a generalized linear model with gamma distribution and log-link function adjusting for demographic characteristics and cooccurring conditions. Out-of-pocket expenditures were estimated using a 2-part model that included logistic and generalized linear model regression. Overlap propensity score weights from logistic regression were used to obtain a balanced sample on hypertension status. RESULTS Among the 393 018 adults, 156 556 (40%) were identified with hypertension. Compared with individuals without hypertension, those with hypertension had $2926 (95% CI, $2681-$3170) higher total expenditures and $328 (95% CI, $300-$355) higher out-of-pocket expenditures. Adults with hypertension had higher total inpatient ($3272 [95% CI, $1458-$5086]) and outpatient ($2189 [95% CI, $2009-$2369]) expenditures when compared with those without hypertension. Hypertension-associated incremental total expenditures were higher for women ($3242 [95% CI, $2915-$3569]) than for men ($2521 [95% CI, $2139-$2904]). CONCLUSIONS Among privately insured US adults, hypertension was associated with higher medical expenditures, including higher inpatient and out-of-pocket expenditures. These findings may help assess the economic value of interventions effective in preventing hypertension.

中文翻译：

---

2021 年私人保险美国成年人的高血压相关支出。


背景 最近没有对高血压相关医疗支出的估计。本研究旨在估计私人保险美国成年人与高血压相关的增量医疗支出。方法 我们使用与 PharMetrics Plus 索赔数据相关联的 IQVIA 的门诊电子病历-US 数据集进行了一项回顾性队列研究。在 18 至 64 岁的私人保险成年人中，高血压在 2021 年被确定为诊断代码为 ≥1 或血压测量值为 ≥140/90 毫米汞柱的 ≥2，或服用 ≥1 抗高血压药物。年度总支出（2021 $US年）是使用广义线性模型估算的，该模型具有伽马分布和对数链接函数，根据人口特征和共存条件进行调整。使用包括 logistic 和广义线性模型回归的 2 部分模型估算自付费用。使用 Logistic 回归的重叠倾向评分权重获得高血压状态的平衡样本。结果 在 393 018 例成人中，156 556 例 （40%） 被诊断为高血压。与没有高血压的人相比，高血压患者的总支出高出 2926 美元（95% CI，2681-3170 美元），自付费用高出 328 美元（95% CI，300-355 美元）。与没有高血压的人相比，成人高血压患者的总住院费用 （$3272 [95% CI， $1458-$5086]）和门诊 （$2189 [95% CI， $2009-$2369]）支出更高。女性（3242 美元 [95% CI，2915-3569 美元]）高于男性（2521 美元 [95% CI，2139-2904 美元]）。 结论 在私人保险的美国成年人中，高血压与较高的医疗支出相关，包括较高的住院和自付费用。这些发现可能有助于评估有效预防高血压的干预措施的经济价值。